152 related articles for article (PubMed ID: 19085836)
1. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity.
Pettus JR; Johnson JJ; Shi Z; Davis JW; Koblinski J; Ghosh S; Liu Y; Ravosa MJ; Frazier S; Stack MS
Histol Histopathol; 2009 Feb; 24(2):197-207. PubMed ID: 19085836
[TBL] [Abstract][Full Text] [Related]
2. Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.
Ghosh S; Koblinski J; Johnson J; Liu Y; Ericsson A; Davis JW; Shi Z; Ravosa MJ; Crawford S; Frazier S; Stack MS
Mol Cancer Res; 2010 Feb; 8(2):145-58. PubMed ID: 20145038
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
Jiang R; Shi Z; Johnson JJ; Liu Y; Stack MS
J Biol Chem; 2011 Mar; 286(11):9127-35. PubMed ID: 21163944
[TBL] [Abstract][Full Text] [Related]
4. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
5. Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.
Johnson JJ; Miller DL; Jiang R; Liu Y; Shi Z; Tarwater L; Williams R; Balsara R; Sauter ER; Stack MS
J Biol Chem; 2016 Mar; 291(13):6936-45. PubMed ID: 26839311
[TBL] [Abstract][Full Text] [Related]
6. Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
Shi Z; Liu Y; Johnson JJ; Stack MS
Mol Cell Biochem; 2011 Nov; 357(1-2):151-61. PubMed ID: 21630091
[TBL] [Abstract][Full Text] [Related]
7. Differential roles of kallikrein-related peptidase 6 in malignant transformation and ΔNp63β-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma.
Kaneko N; Kawano S; Yasuda K; Hashiguchi Y; Sakamoto T; Matsubara R; Goto Y; Jinno T; Maruse Y; Morioka M; Hattori T; Tanaka S; Tanaka H; Kiyoshima T; Nakamura S
Oral Oncol; 2017 Dec; 75():148-157. PubMed ID: 29224812
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma.
Johnson J; Shi Z; Liu Y; Stack MS
Oral Oncol; 2014 May; 50(5):468-77. PubMed ID: 24582884
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Christensen A; Kiss K; Lelkaitis G; Juhl K; Persson M; Charabi BW; Mortensen J; Forman JL; Sørensen AL; Jensen DH; Kjaer A; von Buchwald C
BMC Cancer; 2017 Aug; 17(1):572. PubMed ID: 28841839
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F
BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553
[TBL] [Abstract][Full Text] [Related]
11. ASC contributes to metastasis of oral cavity squamous cell carcinoma.
Wu CS; Chang KP; OuYang CN; Kao HK; Hsueh C; Chen LC; Cheng HY; Liang Y; Liou W; Liang CL; Chang YS
Oncotarget; 2016 Aug; 7(31):50074-50085. PubMed ID: 27367024
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
13. MCP-1 as a potential target to inhibit the bone invasion by oral squamous cell carcinoma.
Quan J; Morrison NA; Johnson NW; Gao J
J Cell Biochem; 2014 Oct; 115(10):1787-98. PubMed ID: 24905457
[TBL] [Abstract][Full Text] [Related]
14. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
15. γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma.
Cheng JC; Chiang MT; Lee CH; Liu SY; Chiu KC; Chou YT; Huang RY; Huang SM; Shieh YS
J Dent Res; 2016 Apr; 95(4):439-45. PubMed ID: 26661712
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Uzawa K; Amelio AL; Kasamatsu A; Saito T; Kita A; Fukamachi M; Sawai Y; Toeda Y; Eizuka K; Hayashi F; Kato-Kase I; Sunohara M; Iyoda M; Koike K; Nakashima D; Ogawara K; Endo-Sakamoto Y; Shiiba M; Takiguchi Y; Yamauchi M; Tanzawa H
Sci Rep; 2019 Aug; 9(1):12179. PubMed ID: 31434965
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of kallikrein-related peptidase-4 in oral cancer.
Papagerakis P; Pannone G; Zheng LI; Athanassiou-Papaefthymiou M; Yamakoshi Y; McGuff HS; Shkeir O; Ghirtis K; Papagerakis S
Anticancer Res; 2015 Apr; 35(4):1861-6. PubMed ID: 25862839
[TBL] [Abstract][Full Text] [Related]
18. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
Liang X; Yang X; Tang Y; Zhou H; Liu X; Xiao L; Gao J; Mao Z
Oral Oncol; 2008 Dec; 44(12):1172-80. PubMed ID: 18486529
[TBL] [Abstract][Full Text] [Related]
19. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Shi Z; Stack MS
Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
[TBL] [Abstract][Full Text] [Related]
20. CSN6 promotes malignant progression of oral squamous cell carcinoma by down-regulating TIMP-2.
Gao WY; Yang G; Wang J; He JM; Wang P
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5419-5428. PubMed ID: 32495877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
